Document is current
Any future updates will be listed below
-
Authors
Malpetti, Maura
Rathore, Saima
Iaccarino, Leonardo
La Joie, Renaud
Tronchin, Giulia
Wessels, Alette M.
Sims, John R.
Pontecorvo, Michael J.
Shcherbinin, Sergey
Rabinovici, Gil D.
-
Funding
Funding for this research was provided by:
Race Against Dementia Alzheimer’s Research UK (ARUK-RADF2021A-010)
Parke Davis Exchange Fellowship in Biomedical Sciences (PD/2020/02)
NIHR Cambridge Biomedical Research Centre (NIHR203312)
NIH/NIA (P30-AG062422, R35 AG072362, U01-AG057195, U01-AG082350)
Alzheimer’s Association
American College of Radiology
Rainwater Charitable Foundation
Laurel Foundation
Shenandoah Foundation
- License Information
-
More Information
Article History
Received: 6 March 2025
Accepted: 10 September 2025
First Online: 6 October 2025
Declarations
:
: The protocols of the interventional and observational trials were reviewed and approved by appropriate ethics committees as required by global trials. All trials were conducted in compliance with the Declaration of Helsinki and the International Conference on Harmonization guideline on good clinical practice (World Medical Association, 1997). All patients provided written informed consent to participate in the trials.
: Unrelated to this work, M.M. provides consultancy to Astex Pharmaceuticals. G.D.R. receives research funding from Avid Radiopharmaceuticals and has served as a scientific consultant to Eli Lilly, which manufacture the FTP tau PET radiotracer evaluated in this manuscript. Unrelated to this work, he receives research funds from GE Healthcare, Genentech and Life Molecular Imaging; has served as a paid scientific consultant to Alector, C2N, Genentech, Johnson & Johnson, Merck, Roche; serves as an Associate Editor for JAMA Neurology. MJP, LI and SS are employees and minor stockholders of Eli Lilly and Company. SR was an employee of Eli Lilly and Company when this work was conducted.
